目的 观察伊伐布雷定对冠状动脉粥样硬化性心脏病（CHD,以下简称：冠心病）合并心律失常患者心率变异性（HRV）的影响,及对心房颤动（AF）的防治效果。方法 本文为前瞻性研究,病例纳入时间为2021年1月—2023年1月,研究对象为焦作市第二人民医院收治的125例CHD合并心律失常患者,采用随机数字表法对入组患者进行分组,分别列为常规组（62例）和联合组（63例）,常规组予常规药物治疗,联合组在常规药物治疗基础上联合伊伐布雷定治疗,比较2组患者治疗前后的HRV指标、血管内皮功能指标、心功能指标改善情况、心房颤动发生率及用药安全性。结果 治疗后,联合组24 h窦性心律RR间期标准差为（88.25±10.36）ms,24 h相邻正常RR间期差值均方根为（50.25±10.61）ms,24 h相邻正常RR间期差值>50 ms百分比为（12.04±3.41）%,均高于常规组[（81.44±10.77）ms、（43.28±10.71）ms、（10.77±3.08）%],组间比较差异具有统计学意义（P<0.05）。治疗后,联合组的血流介导下血管扩张程度为（12.33±3.27）%,硝酸甘油介导下血管内皮舒张程度为（9.83±2.21）%,均高于常规组[（10.25±3.23）%、（8.14±2.03）%]。AF发生率为4.76%（3/63）,低于常规组16.13%（10/62）,差异具有统计学意义（P<0.05）。治疗后,联合组的左室射血分数为（55.35±10.27）%,高于常规组（48.45±10.61）%,左室舒张末期内径为（40.24±10.37）mm,左室后壁厚度为（9.22±2.06）mm,均低于常规组[（46.33±10.28）mm、（10.88±2.46）mm],差异具有统计学意义（P<0.05）。治疗后,联合组的药物相关不良反应发生率为7.94%（5/63）,略高于常规组6.45%（4/62）,组间比较差异无统计学意义（P>0.05）。结论 伊伐布雷定联合常规药物治疗CHD合并心律失常能有效改善患者HRV指标、血管内皮功能及心功能,降低AF发生率,且未增加药物不良反应发生风险。

Objective To observe the effect of ivabradine on heart rate variability（HRV）in coronary heart disease（CHD）patients with arrhythmia and its preventive and therapeutic effects on atrial fibrillation（AF）．Methods This is a prospective cohort study．The 125 CHD patients with arrhythmia were included from January 2021 to January 2023 and divided into the conventional group（62 cases）and the combined group（63 cases）by random number table．The conventional group was treated with conventional drugs,and the combined group was treated with ivabradine additionally．The HRV index,vascular endothelial function index,improvement of cardiac function indicators,incidence of AF and medication safety were compared．Results After treatment,the standard deviation of normal RR intervals in 24 h of the combination group was（88.25±10.36）ms,root mean square of successive RR interval differences in 24 h was（50.25±10.61）ms,and successive RR interval differences>50 ms was（12.04±3.41）%．Compared with the conventional group [（81.44±10.77）ms,（43.28±10.71）ms and（10.77±3.08）%],the above indicators were all higher（P<0.05）．After treatment,the flow-mediated dilation and nitrite-mediated dilation of the combination group were（12.33±3.27）% and（9.83±2.21）%,respectively．Compared with the conventional group（10.25±3.23）% and（8.14±2.03）%）,the above indicators were higher．The incidence of AF was 4.76%（3/63）,which was lower（P<0.05）than the conventional group of 16.13%（10/62）．After treatment,the left ventricular ejection fraction of the combination group was（55.35±10.27）%,which was higher than that of the conventional group（48.45±10.61）%．The left ventricular diastolic diameter was（40.24±10.37）mm and the left ventricular posterior wall thickness was（9.22±2.06）mm．Compared with the conventional group [（46.33±10.28）mm,（10.88±2.46）mm],the above indicators were all lower（P<0.05）．After treatment,the incidence of drug-related side effects in the combination group was 7.94%（5/63）,which was similar to 6.45%（4/62）in the conventional group（P>0.05）．Conclusions The combination of ivabradine and conventional drugs in the treatment of CHD complicated with arrhythmia can effectively improve HRV indicators in patients,promote the recovery of vascular endothelial cell function and cardiac function,reduce the incidence of AF,and do not significantly increase the risk of drug side effects．

目的 探究麻黄附子细辛汤联合参麦注射液治疗缓慢型心律失常的临床疗效。方法 以2015年9月—2016年9月在我院治疗缓慢型心律失常的90例患者作为研究对象,采用随机方式,分为两组,各45例,参麦注射液治疗作为对照组,观察组在对照组给药基础上合用麻黄附子细辛汤治疗,比较分析两组临床治疗效果。结果 观察组治疗总有效率为84.44%,临床疗效明显优于对照组64.44%,两组差异有统计学意义(P<0.05);中医证候评分,观察组治疗后较对照组低,组间差异有统计学意义(P<0.05);治疗后患者心率升高,且观察组优于对照组(P<0.05)。结论 临床治疗缓慢型心律失常,选用麻黄附子细辛汤合用参麦注射液,疗效显著,临床用药可推广应用。

目的 探讨在急诊冠心病快速心律失常患者中应用胺碘酮治疗的临床效果。方法 选取在我院接受治疗的164例冠心病快速心律失常患者进行研究,采用随机数字表法将其随机分为对照组和研究组,每组82例。对照组给予利多卡因治疗,研究组给予胺碘酮治疗,比较两组患者的临床治疗效果及不良反应发生情况,同时比较研究组中不同类型心律失常患者的治疗效果。结果 研究组患者治疗总有效率为89.0%,对照组为64.6%,两组比较均有差异(P＜0.05);采用胺碘酮治疗的研究组患者中,室性早搏患者的治疗总有效率最高,其次为阵发性房颤、持续性房颤、阵发性室性心动过速、室性心动过速,其中室性早搏和阵发性房颤治疗总有效率高于心动过速(P＜0.05)。结论 胺碘酮治疗急诊冠心病快速心律失常在适应症和禁忌症的严格掌握和心率、血压的密切监测的前提下效果更为确切,可作为首选药物应用。

目的 探究酒石酸美托洛尔联合辛伐他汀治疗的临床疗效。方法 对我院2013年2月—2014年5月间收治的80例心律失常患者的临床资料进行回顾性分析,将80例患者随机划分为研究组与对照组,两组各40例;对照组40例心律失常患者给予酒石酸美托洛尔治疗,研究组在对照组的治疗基础上给予辛伐他汀治疗,比较研究组患者与对照组患者的临床治疗效果。结果 研究组患者临床治疗总有效率高于对照组,两组差异有统计学意义(P＜0.05);研究组患者室性期前收缩次数、房性期前收缩次数低于对照组,两组差异有统计学意义(P＜0.05);研究组患者与对照组患者不良反应发生例数无统计学意义(P＞0.05)。结论 心律失常行辛伐他汀治疗的临床疗效显著,值得临床推广应用。

目的 探讨心肌细胞RyR2和L型钙通道的基因变异与室性心律失常和心源性猝死的相关性。方法 回顾分析2010年1月—2012年12月在我院就诊的慢性心力衰竭患者622例的临床资料,并选取同一时期体检中心体检的健康人群516例作为对照组,门诊或者电话随访记录慢性心力衰竭患者的死亡为终点,通过候选基因分析可能具有相关功能的4个基因变异,rs41315858(G1885E)、rs3766871(G1886S)、rs790896(G>A)和rs723672(T>C),采用Logestic、Cox回归分析对4个候选基因变异进行相关性研究。结果 入选622例慢性心力衰竭患者和516例对照组,基因分析结果显示RyR2上的基因变异rs376687lA等位基因携带可以增加慢性心力衰竭患者发生室性心律失常的风险性;校正可能与该疾病相关的危险因素后,rs376687lA等位基因携带会增加心源性死亡和心源性猝死的风险,RyR2上的基因变异rs790896A等位基因携带可以降低心源性猝死风险。结论 RyR2上的基因变异rs376687lA是室性心律失常和心源性猝死的遗传学预测因子,而rs790896A等位基因是慢性心力衰竭患者的保护因子,可降低室性心律失常和心源性猝死的风险。

Objective To investigate the myocardial cells RyR2 and L-type calcium channel gene variants with ventricular arrhythmias and sudden cardiac death correlation. Methods Retrospective analysis of patients with chronic heart failure from January 2010 to December 2012 in our hospital including 622 cases of clinical data, and to select 516 cases of healthy people in medical examination center during the same period as a control group.Clinic or telephone follow-up recorded chronic patients with heart failure and sudden death acting as end. We analyzed possible candidate genes, according to four gene variants related functions, rs41315858 (G1885E), rs3766871 (G1886S), rs790896 (G> A) and rs723672 (T> C), by using Logestic, Cox regression analysis of four candidate gene variants for related research. Results 622 cases of chronic heart failure patients were enrolled and 516 patients in the control group. Genetic analysis showed that the gene variant alleles carried rs376687lA RyR2 may increase in patients with chronic heart failure ventricular arrhythmia risk; correction may be associated with the disease after risk factors, rs376687lA allele carries an increased risk of cardiogenic death and sudden cardiac death, and gene mutation alleles carried on rs790896A RyR2 can reduce the risk of sudden cardiac death. Conclusion Gene mutation rs376687lA RyR2 on genetics is predictor of ventricular arrhythmias and sudden cardiac death, and rs790896A allele is protective factor in patients with chronic heart failure which can be reduced ventricular arrhythmias and sudden cardiac death in risk.